Dashboard
Manage Tickers

HALO


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-halozyme-therapeutics-maintains-90-price-target
HC Wainwright & Co. Reiterates Buy on Halo...
10/15/2025 10:31:43

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $...

leerink-partners-upgrades-halozyme-therapeutics-to-market-perform-announces-70-price-target
Leerink Partners Upgrades Halozyme Therape...
10/14/2025 18:22:24

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Underperform to Market Perform and...

hc-wainwright--co-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-90
HC Wainwright & Co. Maintains Buy on Haloz...
10/02/2025 10:33:51

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the p...

halozyme-to-acquire-elektrofi-in-deal-comprising-of-750m-upfront-payment-and-up-to-three-50m-milestone-payments-contingent-on-three-separate-product-regulatory-approvals-royalty-revenue-contribution-expected-as-early-as-2030
Halozyme To Acquire Elektrofi In Deal Comp...
10/01/2025 11:05:20

benchmark-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-90
Benchmark Maintains Buy on Halozyme Therap...
09/24/2025 12:24:30

Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from...

forecasting-the-future-7-analyst-projections-for-halozyme-therapeutics
Forecasting The Future: 7 Analyst Projecti...
09/22/2025 12:02:57

hc-wainwright--co-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-85
HC Wainwright & Co. Maintains Buy on Haloz...
09/22/2025 10:36:37

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the p...

what-7-analyst-ratings-have-to-say-about-halozyme-therapeutics
What 7 Analyst Ratings Have To Say About H...
08/18/2025 20:01:43

morgan-stanley-maintains-overweight-on-halozyme-therapeutics-raises-price-target-to-80
Morgan Stanley Maintains Overweight on Hal...
08/18/2025 12:52:31

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price t...

jp-morgan-maintains-neutral-on-halozyme-therapeutics-raises-price-target-to-63
JP Morgan Maintains Neutral on Halozyme Th...
08/07/2025 19:17:29

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from ...

what-does-the-market-think-about-halozyme-therapeutics
What Does the Market Think About Halozyme ...
08/07/2025 18:00:45

jmp-securities-maintains-market-outperform-on-halozyme-therapeutics-raises-price-target-to-91
JMP Securities Maintains Market Outperform...
08/06/2025 15:09:07

JMP Securities analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the...

hc-wainwright--co-maintains-buy-on-halozyme-therapeutics-raises-price-target-to-75
HC Wainwright & Co. Maintains Buy on Haloz...
08/06/2025 12:04:34

HC Wainwright & Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the pric...

morgan-stanley-upgrades-halozyme-therapeutics-to-overweight-raises-price-target-to-75
Morgan Stanley Upgrades Halozyme Therapeut...
08/06/2025 11:19:44

Morgan Stanley analyst Vikram Purohit upgrades Halozyme Therapeutics (NASDAQ:HALO) from Equal-Weight to Overweight and raise...

correction-halozyme-therapeutics-q2-adj-eps-154-beats-123-estimate-sales-325719m-beat-281588m-estimate
CORRECTION: Halozyme Therapeutics Q2 Adj. ...
08/05/2025 20:03:21

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of...

halozyme-therapeutics-raises-fy2025-adj-eps-guidance-from-530-570-to-600-640-vs-550-est-raises-fy2025-sales-guidance-from-1200b-1280b-to-1275b-1355b-vs-1252b-est
Halozyme Therapeutics Raises FY2025 Adj EP...
08/05/2025 20:02:20

Halozyme Therapeutics (NASDAQ:HALO) raises FY2025 Adj EPS guidance from $5.30-$5.70 to $6.00-$6.40 vs $5.50 analyst estimate. R...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

earnings-outlook-for-halozyme-therapeutics
Earnings Outlook For Halozyme Therapeutics
08/04/2025 15:04:24

Core News & Articles
'European Commission Approves DARZALEX As ...
07/23/2025 12:42:30

https

1000-invested-in-this-stock-15-years-ago-would-be-worth-this-much-today
$1000 Invested In This Stock 15 Years Ago ...
07/22/2025 20:15:18

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION